Research & Literature

Systolic anterior motion after mitral valve repair: where do we stand in 2015?

Alfieri O, Lapenna E

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2015; (48(3)):344-6 doi:10.1093/ejcts/ezv230.

Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy.

Teo EP, Teoh JG, Hung J

Current opinion in cardiology 2015; (30(5)):475-82 doi:10.1097/HCO.0000000000000200.

Differentiating the athlete's heart from hypertrophic cardiomyopathy.

Wasfy MM, Weiner RB

Current opinion in cardiology 2015; (30(5)):500-5 doi:10.1097/HCO.0000000000000203.

Family History of Sudden Death Should Be a Primary Indication for Implantable Cardioverter Defibrillator in Hypertrophic Cardiomyopathy.

Maron MS

The Canadian journal of cardiology 2015; (31(11)):1402-6.

Symptom assessment and exercise impairment in surgical decision making in hypertrophic obstructive cardiomyopathy: Relationship to outcomes.

Desai MY, Smedira NG, Bhonsale A, et al.

The Journal of thoracic and cardiovascular surgery 2015; (150(4)):928-35.e1.

A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction Therapy in Patients With Hypertrophic Cardiomyopathy.

Liebregts M, Vriesendorp PA, Mahmoodi BK, et al.

JACC. Heart failure 2015; (3(11)):896-905.

Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies.

Maron BJ, Rowin EJ, Casey SA, et al.

Circulation 2016; (133(1)):62-73 doi:10.1161/CIRCULATIONAHA.115.017633.

Relationship of basal-septal fibrosis with LV outflow tract obstruction in hypertrophic cardiomyopathy: insights from cardiac magnetic resonance analysis.

Nakamura T, Iwanaga Y, Yasuda M, et al.

The international journal of cardiovascular imaging 2016; (32(4)):613-20 doi:10.1007/s10554-015-0806-8.

Through Thick and Thin: What Are the Septal Thickness Limits for Alcohol Septal Ablation?

Fifer MA

Circulation. Cardiovascular interventions 2016; (9(3)):e003588.

Prognostic Value of LGE-CMR in HCM: A Meta-Analysis.

Weng Z, Yao J, Chan RH, et al.

JACC. Cardiovascular imaging 2016; (9(12)):1392-1402 doi:10.1016/j.jcmg.2016.02.031.

Hypertrophic obstructive cardiomyopathy.

Veselka J, Anavekar NS, Charron P

Lancet (London, England) 2017; (389(10075)):1253-1267 doi:10.1016/S0140-6736(16)31321-6.

Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy.

Wang W, Lian Z, Rowin EJ, et al.

Circulation. Arrhythmia and electrophysiology 2017; (10(3)) doi:10.1161/CIRCEP.116.004604.

Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage.

Viswanathan SK, Sanders HK, McNamara JW, et al.

PloS one 2017; (12(11)):e0187948 doi:10.1371/journal.pone.0187948.

Role of Exercise Testing in Hypertrophic Cardiomyopathy.

Rowin EJ, Maron BJ, Olivotto I, Maron MS

JACC. Cardiovascular imaging 2017; (10(11)):1374-1386 doi:10.1016/j.jcmg.2017.07.016.

Predicting the Future in Hypertrophic Cardiomyopathy.

Ho CY, Link MS

Circulation 2018; (137(10)):1024-1026 doi:10.1161/CIRCULATIONAHA.117.032627.

Standardized Goal-Directed Valsalva Maneuver for Assessment of Inducible Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy.

Kumar S, Van Ness G, Bender A, et al.

Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2018; (31(7)):791-798 doi:10.1016/j.echo.2018.01.022.

The effects of septal myectomy and alcohol septal ablation for hypertrophic cardiomyopathy on the cardiac conduction system.

Fitzgerald P, Kusumoto F

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2018; (52(3)):403-408 doi:10.1007/s10840-018-0433-0.

Conventional cardiopulmonary resuscitation-induced refractory cardiac arrest due to latent left ventricular outflow tract obstruction due to a sigmoid septum: a case report.

Yamagishi T, Tanabe T, Fujita H, et al.

Journal of medical case reports 2018; (12(1)):229 doi:10.1186/s13256-018-1767-z.

Cardiac pacing in patients with hypertrophic obstructive cardiomyopathy.

Tolosana JM, Trucco E

Global cardiology science & practice 2018; (2018(3)):29 doi:10.21542/gcsp.2018.29.

Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: Systematic review and meta-analysis.

Osman M, Kheiri B, Osman K, et al.

Clinical cardiology 2019; (42(1)):190-197 doi:10.1002/clc.23113.

Cardiology: hypertrophic cardiomyopathy.

, Firth J

Clinical medicine (London, England) 2019; (19(1)):61-63 doi:10.7861/clinmedicine.19-1-61.

The relationship between the quantitative extent of late gadolinium enhancement and burden of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: A delayed contrast-enhanced magnetic resonance study.

Weissler-Snir A, Hindieh W, Spears DA, et al.

Journal of cardiovascular electrophysiology 2019; (30(5)):651-657 doi:10.1111/jce.13855.

Modulating myosin function to treat hypertrophic cardiomyopathy.

Fernández-Ruiz I

Nature reviews. Cardiology 2019; (16(4)):201 doi:10.1038/s41569-019-0170-9.

Survival After Myectomy for Obstructive Hypertrophic Cardiomyopathy: What Causes Late Mortality?

Nguyen A, Schaff HV, Nishimura RA, et al.

The Annals of thoracic surgery 2019; (108(3)):723-729 doi:10.1016/j.athoracsur.2019.03.026.

Yield of Clinical Screening for Hypertrophic Cardiomyopathy in Child First-Degree Relatives.

Norrish G, Jager J, Field E, et al.

Circulation 2019; (140(3)):184-192 doi:10.1161/CIRCULATIONAHA.118.038846.

A Case of an Acutely Ill Adult Athlete with Previously Undiagnosed Hypertrophic Obstructive Cardiomyopathy.

Minckler MR, Maker M

Cureus 2019; (11(6)):e4875 doi:10.7759/cureus.4875.

Mitral Valve Disease in Hypertrophic Cardiomyopathy:Evaluation and Management.

Jain CC, Newman DB, Geske JB

Current cardiology reports 2019; (21(11)):136 doi:10.1007/s11886-019-1231-8.

The Hypertrophic Cardiomyopathy Phenotype Viewed Through the Prism of Multimodality Imaging: Clinical and Etiologic Implications.

Rowin EJ, Maron BJ, Maron MS

JACC. Cardiovascular imaging 2020; (13(9)):2002-2016 doi:10.1016/j.jcmg.2019.09.020.

Cardiac troponin I is associated with non-sustained ventricular tachycardia in patients with hypertrophic obstructive cardiomyopathy.

Zhou Y, Yu M, Yuan J, et al.

Heart and vessels 2020; (35(6)):876-885 doi:10.1007/s00380-019-01549-0.

Myocardial tissue characterization by gadolinium-enhanced cardiac magnetic resonance imaging for risk stratification of adverse events in hypertrophic cardiomyopathy.

Raiker N, Vullaganti S, Collins JD, et al.

The international journal of cardiovascular imaging 2020; (36(6)):1147-1156 doi:10.1007/s10554-020-01808-6.

Alcohol septal ablation: A useful tool in our arsenal against hypertrophic obstructive cardiomyopathy.

Savarimuthu S, Harky A

Journal of cardiac surgery 2020; (35(8)):2017-2024 doi:10.1111/jocs.14815.

Reverse remodeling after percutaneous transluminal septal myocardial ablation in severe but asymptomatic LVOT obstruction (RASTA) study: Rationale and design of transcatheter septal reduction in asymptomatic patients with severe hypertrophic obstructive cardiomyopathy.

Arslan F, Akdim F, Ten Berg JM

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2021; (97(3)):488-492 doi:10.1002/ccd.29178.

Evidence That Subcutaneous Implantable Cardioverter-Defibrillators Are Effective and Reliable in Hypertrophic Cardiomyopathy.

Maron MS, Steiger N, Burrows A, et al.

JACC. Clinical electrophysiology 2020; (6(8)):1019-1021 doi:10.1016/j.jacep.2020.03.015.

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.

Olivotto I, Oreziak A, Barriales-Villa R, et al.

Lancet (London, England) 2020; (396(10253)):759-769 doi:10.1016/S0140-6736(20)31792-X.

Cardiac magnetic resonance T2 mapping and feature tracking in athlete's heart and HCM.

Gastl M, Lachmann V, Christidi A, et al.

European radiology 2021; (31(5)):2768-2777 doi:10.1007/s00330-020-07289-4.

Texture analysis applied in T1 maps and extracellular volume obtained using cardiac MRI in the diagnosis of hypertrophic cardiomyopathy and hypertensive heart disease compared with normal controls.

Shi RY, Wu R, An DL, et al.

Clinical radiology 2021; (76(3)):236.e9-236.e19 doi:10.1016/j.crad.2020.11.001.

Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity.

Harper AR, Goel A, Grace C, et al.

Nature genetics 2021; (53(2)):135-142 doi:10.1038/s41588-020-00764-0.

Combined Effect of Mediterranean Diet and Aerobic Exercise on Weight Loss and Clinical Status in Obese Symptomatic Patients with Hypertrophic Cardiomyopathy.

Limongelli G, Monda E, D'Aponte A, et al.

Heart failure clinics 2021; (17(2)):303-313 doi:10.1016/j.hfc.2021.01.003.

Pulmonary Embolism in a Patient With Hypertrophic Obstructive Cardiomyopathy: Think Outside "the Box".

Wartenweiler M, Dellas Buser T, Joerg L, et al.

The Canadian journal of cardiology 2021; (37(8)):1275-1277 doi:10.1016/j.cjca.2021.02.019.

Prognostic role of left ventricular apical aneurysm in hypertrophic cardiomyopathy: A systematic review and meta-analysis.

Papanastasiou CA, Zegkos T, Karamitsos TD, et al.

International journal of cardiology 2021; (332()):127-132 doi:10.1016/j.ijcard.2021.03.056.

Left ventricular involvement assessed by LGE-CMR in predicting the risk of adverse outcomes of arrhythmogenic cardiomyopathy with ICDs.

Zhang N, Song Y, Hua W, et al.

International journal of cardiology 2021; (337()):79-85 doi:10.1016/j.ijcard.2021.04.015.

Hypertrophic cardiomyopathy: diagnosis and therapeutic options.

Gluckman TJ

The American journal of managed care 2021; (27(6 Suppl)):S111-S117 doi:10.37765/ajmc.2021.88628.

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Spertus JA, Fine JT, Elliott P, et al.

Lancet (London, England) 2021; (397(10293)):2467-2475 doi:10.1016/S0140-6736(21)00763-7.

Myocardial Bridge or Something Else?

Wang X, Rastegar H, Rowin EJ, et al.

Journal of cardiothoracic and vascular anesthesia 2022; (36(1)):332-337 doi:10.1053/j.jvca.2021.08.010.

Sex Differences in Hypertrophic Cardiomyopathy: Interaction With Genetics and Environment.

Butters A, Lakdawala NK, Ingles J

Current heart failure reports 2021; (18(5)):264-273 doi:10.1007/s11897-021-00526-x.

Development and piloting of four decision aids for implantable cardioverter-defibrillators in different media formats.

Wallace BC, Jones J, Masoudi FA, et al.

Pacing and clinical electrophysiology : PACE 2021; (44(11)):1842-1852 doi:10.1111/pace.14365.

Hypertrophic Cardiomyopathy Diagnosed on Point-of-Care Echocardiogram in an Elderly Patient With Syncope.

Stoll CM, Carr M, Naraghi L

Cureus 2021; (13(8)):e17008 doi:10.7759/cureus.17008.

Impact of cibenzoline treatment on left ventricular remodelling and prognosis in hypertrophic obstructive cardiomyopathy.

Hamada M, Shigematsu Y, Ikeda S, et al.

ESC heart failure 2021; (8(6)):4832-4842 doi:10.1002/ehf2.13672.

The Risk of Sudden Death in Children with Hypertrophic Cardiomyopathy.

Norrish G, Kaski JP

Heart failure clinics 2022; (18(1)):9-18 doi:10.1016/j.hfc.2021.07.012.

Interplay of Genotype and Substrate Stiffness in Driving the Hypertrophic Cardiomyopathy Phenotype in iPSC-Micro-Heart Muscle Arrays.

Guo J, Jiang H, Oguntuyo K, et al.

Cellular and molecular bioengineering 2021; (14(5)):409-425 doi:10.1007/s12195-021-00684-x.

The Impact of Ischemia Assessed by Magnetic Resonance on Functional, Arrhythmic, and Imaging Features of Hypertrophic Cardiomyopathy.

Aguiar Rosa S, Thomas B, Fiarresga A, et al.

Frontiers in cardiovascular medicine 2021; (8()):761860 doi:10.3389/fcvm.2021.761860.

Image-Based Computational Hemodynamics Analysis of Systolic Obstruction in Hypertrophic Cardiomyopathy.

Fumagalli I, Vitullo P, Vergara C, et al.

Frontiers in physiology 2021; (12()):787082 doi:10.3389/fphys.2021.787082.

Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy.

Liu J, Wang D, Ruan J, et al.

BMC medicine 2022; (20(1)):21 doi:10.1186/s12916-021-02219-7.

Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy.

Zhou M, Ta S, Hahn RT, et al.

JAMA cardiology 2022; (7(5)):529-538 doi:10.1001/jamacardio.2022.0259.

Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.

Desai MY, Owens A, Geske JB, et al.

Circulation 2023; (147(11)):850-863 doi:10.1161/CIRCULATIONAHA.122.062534.

Experiences Implementing a Suite of Decision Aids for Implantable Cardioverter Defibrillators: Qualitative Insights From the DECIDE-ICD Trial.

Knoepke CE, Wallace BC, Allen LA, et al.

Circulation. Cardiovascular quality and outcomes 2022; (15(11)):e009352 doi:10.1161/CIRCOUTCOMES.122.009352.

Septal Myectomy or Alcohol Ablation for Hypertrophic Cardiomyopathy: A Nationwide Inpatient Sample (NIS) Database Analysis.

Ullah W, Warner E, Khandait H, et al.

Cardiovascular revascularization medicine : including molecular interventions 2023; (50()):54-58 doi:10.1016/j.carrev.2023.01.013.

Altered coronary artery function, arteriogenesis and endothelial YAP signaling in postnatal hypertrophic cardiomyopathy.

Langa P, Marszalek RJ, Warren CM, et al.

Frontiers in physiology 2023; (14()):1136852 doi:10.3389/fphys.2023.1136852.

Arrhythmic Risk Stratification among Patients with Hypertrophic Cardiomyopathy.

Santoro F, Mango F, Mallardi A, et al.

Journal of clinical medicine 2023; (12(10)) doi:10.3390/jcm12103397.

Multimodality imaging of hypertrophic cardiomyopathy.

Dong T, Gilliland Y, Kramer CM, et al.

Progress in cardiovascular diseases 2023; (80()):14-24 doi:10.1016/j.pcad.2023.08.004.

Randomized Controlled Trial of Moderate- and High-Intensity Exercise Training in Patients With Hypertrophic Cardiomyopathy: Effects on Fitness and Cardiovascular Response to Exercise.

MacNamara JP, Dias KA, Hearon CM, et al.

Journal of the American Heart Association 2023; (12(20)):e031399 doi:10.1161/JAHA.123.031399.

Mechanical Resistance to Micro-Heart Tissue Contractility unveils early Structural and Functional Pathology in iPSC Models of Hypertrophic Cardiomyopathy.

Guo J, Jiang H, Schuftan D, et al.

bioRxiv : the preprint server for biology 2023; doi:10.1101/2023.10.30.564856.

Distinguishing left ventricular hypertrophy from hypertrophic cardiomyopathy in adolescents: a longitudinal observation study.

Forså MI, Smedsrud MK, Haugaa KH, et al.

European journal of preventive cardiology 2024; (31(5)):591-598 doi:10.1093/eurjpc/zwad361.

Tailored Planning of Surgical Myectomy in Obstructive Hypertrophic Cardiomyopathy.

Koo HJ, Lee SA, Jung SH, et al.

Radiographics : a review publication of the Radiological Society of North America, Inc 2024; (44(1)):e230050 doi:10.1148/rg.230050.

Interventions in Hypertrophic Obstructive Cardiomyopathy.

Ding WY, Meah MN, Stables R, Cooper RM

The Canadian journal of cardiology 2024; (40(5)):833-842 doi:10.1016/j.cjca.2023.12.001.

Neonatal hypertrophic cardiomyopathy with dyspnoea as the first symptom: a case report.

Li X, Hong SJ, Hong H, et al.

Frontiers in pediatrics 2023; (11()):1295539 doi:10.3389/fped.2023.1295539.

The Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy.

Maron MS, Rowin EJ, Maron BJ

The American journal of cardiology 2024; (212S()):S64-S76 doi:10.1016/j.amjcard.2023.10.076.

Obstruction in Hypertrophic Cardiomyopathy: Many Faces.

Abbasi M, Ong KC, Newman DB, et al.

Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2024; (37(6)):613-625 doi:10.1016/j.echo.2024.02.010.

Frequency of misdiagnosis in hypertrophic cardiomyopathy.

Nielsen SK, Rasmussen TB, Hey TM, et al.

European heart journal. Quality of care & clinical outcomes 2025; (11(2)):105-112 doi:10.1093/ehjqcco/qcae031.

2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.

Ommen SR, Ho CY, Asif IM, et al.

Circulation 2024; (149(23)):e1239-e1311 doi:10.1161/CIR.0000000000001250.

2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.

, Ommen SR, Ho CY, et al.

Journal of the American College of Cardiology 2024; (83(23)):2324-2405 doi:10.1016/j.jacc.2024.02.014.

Evolving Strategies for the Management of Obstructive Hypertrophic Cardiomyopathy.

Liang LW, Lumish HS, Sewanan LR, et al.

Journal of cardiac failure 2024; (30(9)):1136-1153 doi:10.1016/j.cardfail.2024.04.024.

Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond.

Gaballa A, Jadam S, Desai MY

Expert opinion on pharmacotherapy 2024; (25(7)):915-924 doi:10.1080/14656566.2024.2362902.

Major Cardiac Events in Patients and Relatives With Hereditary Hypertrophic Cardiomyopathy.

Nielsen SK, Hansen FG, Rasmussen TB, et al.

JACC. Advances 2023; (2(8)):100604 doi:10.1016/j.jacadv.2023.100604.

Prognosis of Patients with Hypertrophic Obstructive Cardiomyopathy: A Multicenter Cohort Study with Data-Driven Propensity Score Matching Analysis.

He Y, Ma H, Sun N, et al.

Reviews in cardiovascular medicine 2023; (24(9)):267 doi:10.31083/j.rcm2409267.

Left ventricular stent-graft implantation for severe left ventricular outflow tract obstruction after transcatheter mitral valve implantation.

Ruge H, Krane M

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2024; (66(2)) doi:10.1093/ejcts/ezae305.

Redefining Management in Hypertrophic Cardiomyopathy: The Role and Challenges of Exercise Rehabilitation.

Verma A, Anand A, Patel VA, et al.

Cardiology in review 2024; doi:10.1097/CRD.0000000000000766.

Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response.

Owens AT, Desai M, Wheeler MT, et al.

Journal of the American Heart Association 2024; (13(17)):e033767 doi:10.1161/JAHA.124.033767.

A Cautionary Tale of Hypertrophic Cardiomyopathy-From "Benign" Left Ventricular Hypertrophy to Stroke, Atrial Fibrillation, and Molecular Genetic Diagnostics: A Case Report and Review of Literature.

Gencheva D, Angelova P, Genova K, et al.

International journal of molecular sciences 2024; (25(17)) doi:10.3390/ijms25179385.

Advancements in the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Comprehensive Review.

Gill R, Siddiqui A, Yee B, et al.

Journal of cardiovascular development and disease 2024; (11(9)) doi:10.3390/jcdd11090290.

The Diagnosis and Treatment of Hypertrophic Cardiomyopathy.

Möbius-Winkler MN, Laufs U, Lenk K

Deutsches Arzteblatt international 2024; (121(24)):805-811.

What Is the Significance of Greater Global Wasted Work in Patients With Apical Hypertrophic Cardiomyopathy and Apical Aneurysm? Is It the Chicken or the Egg?

Pollick C

Echocardiography (Mount Kisco, N.Y.) 2024; (41(10)):e70010 doi:10.1111/echo.70010.

Procedural Volume and Outcomes After Septal Reduction Therapies in Hypertrophic Obstructive Cardiomyopathy.

Patel N, Shetty NS, Gaonkar M, et al.

Journal of the American Heart Association 2024; (13(21)):e036387 doi:10.1161/JAHA.124.036387.

Hypertrophic Cardiomyopathy as a Form of Heart Failure with Preserved Ejection Fraction: Diagnosis, Drugs, and Procedures.

Banthiya S, Check L, Atkins J

US cardiology 2024; (18()):e17 doi:10.15420/usc.2023.21.

Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program.

Desai MY, Seto D, Cheung M, et al.

Circulation. Heart failure 2025; (18(1)):e012441 doi:10.1161/CIRCHEARTFAILURE.124.012441.

Differences in the Impact of Left Ventricular Outflow Tract Obstruction on Intraventricular Pressure Gradient in Feline Hypertrophic Cardiomyopathy.

Hirose M, Watanabe M, Takeuchi A, et al.

Animals : an open access journal from MDPI 2024; (14(22)) doi:10.3390/ani14223320.

The clinical utility of cardiac myosin inhibitors for the management of hypertrophic cardiomyopathy: a scoping review.

Othman L, Koskina L, Huerta N, Rao SJ

Heart failure reviews 2025; (30(2)):453-467 doi:10.1007/s10741-024-10476-w.

Rethinking Risk in Hypertrophic Cardiomyopathy: Assessing the Role of Myocardial Fibrosis and Left Ventricular Hypertrophy in Sudden Cardiac Death.

Badr A, Farina J, Arsanjani R, et al.

Mayo Clinic proceedings. Innovations, quality & outcomes 2024; (8(6)):517-520 doi:10.1016/j.mayocpiqo.2024.09.001.

[The evolving landscape of hypertrophic cardiomyopathy management: a review of the updated AHA/ACC/multisociety guidelines].

Bertero E, Canepa M, Pieroni M, Olivotto I

Giornale italiano di cardiologia (2006) 2025; (26(3)):185-194 doi:10.1714/4454.44487.

The incremental role of late gadolinium enhancement in risk stratifying high risk patients with hypertrophic cardiomyopathy.

Ravi SN, O'Shea M, Baqal O, et al.

American heart journal 2025; (289()):28-37 doi:10.1016/j.ahj.2025.04.030.

Predictors of sudden cardiac death in postmyectomy hypertrophic cardiomyopathy with obstruction.

Zhu C, Yang S, Zhao K, et al.

Heart rhythm 2026; (23(5)):1196-1203 doi:10.1016/j.hrthm.2025.05.008.

Mavacamten Cardiac Myosin Inhibitor: Clinical Applications and Future Perspectives.

Ramadan MM, Al-Najjar RA, Abady RS, et al.

Cureus 2025; (17(4)):e82722 doi:10.7759/cureus.82722.

Current management of hypertrophic cardiomyopathy.

Sikand N, Stendahl J, Sen S, et al.

BMJ (Clinical research ed.) 2025; (389()):e077274 doi:10.1136/bmj-2023-077274.

Late Gadolinium Enhancement and Electrocardiographic Associations in Hypertrophic Cardiomyopathy.

Asfour I, Karim S, Tabraiz SA, et al.

Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc 2025; (30(4)):e70077 doi:10.1111/anec.70077.

Cardiac myosin inhibitors in hypertrophic cardiomyopathy.

Lim J, Kim HK

Journal of cardiovascular imaging 2025; (33(1)):7 doi:10.1186/s44348-025-00052-7.

Mavacamten in Symptomatic Patients Resistant to Previous Advanced Therapy for Obstructive Hypertrophic Cardiomyopathy.

Massera D, Adlestein E, Frejat S, et al.

Journal of the American Heart Association 2025; (14(15)):e041565 doi:10.1161/JAHA.125.041565.

Short- and Long-Term Outcomes of Obstructive and Non-Obstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis.

Lo HZ, Low CE, Yau CE, et al.

Heart, lung & circulation 2025; (34(9)):e104-e124 doi:10.1016/j.hlc.2025.03.011.

Prognostic value of late gadolinium enhancement on cardiac magnetic resonance imaging for non-sustained ventricular tachycardia and sudden cardiac death in hypertrophic cardiomyopathy: a meta-analysis.

Siddiqi AK, Maniya MT, Bilen O, et al.

European radiology 2026; (36(2)):1158-1169 doi:10.1007/s00330-025-11961-y.

Cardiopulmonary Exercise Testing for Characterization of Hypertrophic Cardiomyopathy: A Meta-Analysis.

Landsteiner I, Masri A, Saberi S, et al.

Journal of the American Heart Association 2025; (14(17)):e039551 doi:10.1161/JAHA.124.039551.

Conduction block and thin and hypokinetic myocardial segments in feline hypertrophic cardiomyopathy.

Sung Y, Park J, Chae Y, et al.

Veterinarni medicina 2025; (70(8)):302-306 doi:10.17221/14/2025-VETMED.

The Evolving Landscape of Hypertrophic Cardiomyopathy: Phenocopies and Diagnostic Pathways in Hypertrophic Cardiomyopathy.

Son JW, Nam JH, Choi KU, Hong GR

Heart failure clinics 2025; (21(4)):533-547 doi:10.1016/j.hfc.2025.06.004.

Sudden Death Risk Assessment in Hypertrophic Cardiomyopathy Across the Lifespan: Reconciling the American and European Approaches.

Al Samarraie A, Petzl A, Cadrin-Tourigny J, Tadros R

Heart failure clinics 2025; (21(4)):599-610 doi:10.1016/j.hfc.2025.07.002.

Scar architecture as a structural biomarker of ventricular arrhythmias and sudden cardiac death in patients with hypertrophic cardiomyopathy: a cardiac magnetic resonance study.

Francia P, Falasconi G, Musumeci MB, et al.

European heart journal. Cardiovascular Imaging 2026; (27(3)):400-412 doi:10.1093/ehjci/jeaf297.

Exercise training in hypertrophic cardiomyopathy: a meta-analysis of randomised trials with trial sequential analysis.

Correia VM, Morales Ribeiro V, Henkes Machado R, et al.

Heart (British Cardiac Society) 2025; doi:10.1136/heartjnl-2025-326377.

Genotype-phenotype associations in sarcomeric hypertrophic cardiomyopathy associated with mutations in the MYBPC3 gene: Systematic review and meta-analysis.

Nogueira-Garcia B, Pinheiro D, Gregório C, et al.

Journal of cardiology 2026; (87(3)):205-211 doi:10.1016/j.jjcc.2025.12.007.

Case Report: Genomic and clinical insights into MYBPC3-related hypertrophic cardiomyopathy in Ecuadorian patients: implications for sudden cardiac death risk.

Paz-Cruz E, Guevara-Ramírez P, Tamayo-Trujillo R, et al.

Frontiers in cardiovascular medicine 2025; (12()):1693244 doi:10.3389/fcvm.2025.1693244.

Septal reduction therapies for obstructive hypertrophic cardiomyopathy: Current strategies and evolving innovations.

Cui H, Lai Y, Schaff HV

Trends in cardiovascular medicine 2026; doi:10.1016/j.tcm.2026.02.004.

Serial Myocardial Fibrosis Assessments Predict Outcomes in Patients With Hypertrophic Cardiomyopathy.

Tang Y, Chen X, Zhao K, et al.

JACC. Cardiovascular imaging 2026; (19(6)):688-701 doi:10.1016/j.jcmg.2026.01.008.